Sulfonamide-derived hydrazone compounds and their Pd (II) complexes: Synthesis, spectroscopic characterization, X-ray structure determination, in vitro antibacterial activity and computational studies


ÖZBEK N., ÖZDEMİR ÖZMEN Ü. , Altun A. F. , ŞAHİN E.

JOURNAL OF MOLECULAR STRUCTURE, vol.1196, pp.707-719, 2019 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 1196
  • Publication Date: 2019
  • Doi Number: 10.1016/j.molstruc.2019.07.016
  • Title of Journal : JOURNAL OF MOLECULAR STRUCTURE
  • Page Numbers: pp.707-719

Abstract

A new sulfonamide-derived prophane sulfonyl hydrazone compounds: 2-hydroxy- acetophenonepro-phanesulfonylhydrazone (afpsh), 5-Cl-2-hydroxyacetophenoneprophane sulfonylhydrazone (5-Clafpsh), 3,5-di-tert-butyl-2-hydroxybenzaldehydeprophanesulfonyl hydrazone (3,5-tbsalpsh) and their Pd(II) complexes were synthesized. The characterization of all compounds was characterized by H-1 NMR, C-13 NMR, FT-IR, Mass spectral data, elemental analysis and magnetic susceptibility measurements. The crystal structure of afpsh was determined by single crystal X-ray diffraction methods. H-1 and C-13 shielding tensors of afpsh were calculated with GlAO/DFT/B3LYP/6-311++G(d,p) methods in DMSO. Molecular electrostatic potential surface and frontier orbital analysis were also carried out. HOMO-LUMO energy gap was calculated which allowed the calculation of relative reactivity descriptors like chemical hardness, chemical inertness, chemical potential, nucleophilicity and electrophilicity index of all compounds. It has been observed that the calculated band gaps for Pd (II) complexes are much smaller than ligands. The microbiological effect of ligands and Pd(II) complexes were tested against six human pathogenic bacteria (three Gram-positive and three Gram-negative strains) by using microdilution (as MICs) and disc diffusion (as mm zone) methods. It was found that all compounds, in particular Pd (II) complexes, were more active than sulfonyl hydrazones. Published by Elsevier B.V.